News

August 4, 2016August 4, 2016

Sandoz Reports Biosimilar for Enbrel Effectively Treated Plaque Psoriasis in Phase 3 Study

News

Sandoz, a division of Novartis, reported that its clinical trial comparing the efficacy and the safety of GP2015, its biosimilar candidate to Enbrel (etanercept), met its primary endpoint — effectiveness ... Read more

August 3, 2016August 3, 2016

Infliximab Biosimilar as Effective as Remicade in Treating Psoriasis, Study Finds

News

Psoriasis patients using the anti-inflammatory drug Remicade (infliximab) who switched to an infliximab biosimilar had no significant change in clinical response or reported adverse events, researches investigating the medication changed reported. The article, “The ... Read more

August 2, 2016August 2, 2016

Generic Biologics for Psoriasis Similar in Safety and Efficacy to Brand Names, Study Finds

News

Researchers have found that generic forms of a biologic drug used to treat inflammatory diseases such as psoriasis and rheumatoid arthritis are as safe and effective as the brand-name equivalent. ... Read more

August 1, 2016August 1, 2016

Moderate-to-Severe Psoriasis May Be Treated Using Mix of Biologic and Light Therapies

News

A combination of biologic and phototherapy treatments appear to be a viable clinical strategy for people with moderate-to-severe psoriasis who do not respond to either as monotherapy, according to a recent systematic review. ... Read more

July 29, 2016July 29, 2016

Psoriasis and Cardiovascular Symptoms: What to Know About Improving Health

News

Psoriasis is a chronic inflammatory disease with its most visible effects on the skin. However, psoriasis patients are at an elevated risk for many other conditions, particularly cardiovascular disease. In ... Read more

July 27, 2016

Gut Microbiome Could Be a Therapeutic Target to Manage Psoriasis

News

Interaction between the the immune system and the gut’s microbiome in the development of psoriasis and its accompanying lesions was the focus of the study, “Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response,” published ... Read more

July 25, 2016

Review Details Common Cellular, Immunological, Treatment Traits of Psoriasis, Inflammatory Bowel Disease

News

Psoriasis and inflammatory bowel disease (IBD), both chronic and inflammatory diseases, coexist in many patients and share genetic profiles. In a recent review, researchers explores and described the existing evidence ... Read more

July 22, 2016July 22, 2016

Erythrodermic Psoriasis Drug Review Calls for Guideline Update, Biologic Meds Included

News

Researchers at the University of California, Los Angeles recently provided a research review concerning treatment of erythrodermic psoriasis, a rare but severe version of common plaque psoriasis that effects at least 75% of the body. The ... Read more

July 21, 2016

Psoriasis Drug Siliq Supported by FDA Panel Despite Suicide Concerns

News

The U.S. FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously for the approval of Valeant Pharmaceuticals’ Siliq (brodalumab). The full FDA is expected to make a decision on approval of the ... Read more